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Apolipoprotein E (apoE) is an important determinant
for the uptake of triglyceride-rich lipoproteins and
emulsions by the liver, but the intracellular pathway of
apoE following particle internalization is poorly de-
fined. In the present study, we investigated whether
retroendocytosis is a unique feature of apoE as com-
pared with apoB by studying the intracellular fate of
very low density lipoprotein-sized apoE-containing trig-
lyceride-rich emulsion particles and LDL after LDLr-
mediated uptake. Incubation of HepG2 cells with
[3H]cholesteryl oleate-labeled particles at 37 °C led to a
rapid release of [3H]cholesterol within 30 min for both
LDL and emulsion particles. In contrast, emulsion-de-
rived 125I-apoE was more resistant to degradation (>120
min) than LDL-derived 125I-apoB (30 min). Incubation at
18 °C, which allows endosomal uptake but prevents ly-
sosomal degradation, with subsequent incubation at
37 °C resulted in a time-dependent release of intact apoE
from the cells (up to 14% of the endocytosed apoE at 4 h).
The release of apoE was accelerated by the presence of
protein-free emulsion (20%) or high density lipoprotein
(26%). Retroendocytosis of intact particles could be ex-
cluded since little intact [3H]cholesteryl oleate was re-
leased (<3%). In contrast, the degradation of LDL was
complete with virtually no secretion of intact apoB into
the medium. The intracellular stability of apoE was also
demonstrated after hepatic uptake in C57Bl/6 mice. In-
travenous injection of 125I-apoE and [3H]cholesteryl
oleate-labeled emulsions resulted in efficient LDLr-me-
diated uptake of both components by the liver (45–50%
of the injected dose after 20 min). At 1 h after injection,
only 15–20% of the hepatic 125I-apoE was degraded,
whereas 75% of the [3H]cholesteryl oleate was hydro-
lyzed. From these data we conclude that following
LDLr-mediated internalization by liver cells, apoE can
escape degradation and can be resecreted. This se-
quence of events may allow apoE to participate in its
hypothesized intracellular functions such as mediator
of the post-lysosomal trafficking of lipids and very low
density lipoprotein assembly.
Apolipoprotein E (apoE)1 plays a key role in the hepatic
metabolism of triglyceride (TG)-rich lipoproteins such as chy-
lomicrons and very low density lipoproteins (VLDL) (1–3) and
TG-rich emulsions (4–5). In the blood, these particles are con-
verted into TG-rich remnants through the hydrolysis of core TG
by lipoprotein lipase (LPL) and the concomitant enrichment
with apoE. Various apoE-recognizing systems have been pro-
posed to participate in remnant removal, including the low
density receptor (LDLr) (6–8), a distinct specific apoE receptor
(1, 9), the LDLr-related protein (8, 10, 11), and heparan sulfate
proteoglycans (HSPG) alone (12, 13) or in concert with LDLr-
related protein (5, 14). However, the LDLr pathway plays a
substantially greater role in the overall clearance of TG-rich
lipoprotein remnants in mice than the non-LDLr pathway (15,
16). It has been shown that the affinity of TG-rich lipoproteins
and emulsions for the LDLr pathway and non-LDLr pathway is
governed by their particle size. Whereas large particles are
mainly processed via the liver-specific non-LDLr recognition
site, small particles (,50 nm) are almost exclusively recognized
and taken up by the LDLr (17, 18).
The intracellular metabolism of TG-rich remnants may be
far more complex than for LDL, of which both the protein and
lipid components are completely degraded within perinuclear
lysosomes while the receptor recycles back to the cell surface
(19, 20). Whereas LDL shows a single interaction of apoB with
the LDLr, four molecules of apoE on TG-containing lipopro-
teins can bind a single LDLr (21). In addition, apoE-containing
lipoproteins can interact with multiple LDLrs (22). In either
case, when lipoproteins or emulsions are provided with at least
four molecules of apoE, their affinity for the LDLr is 20–25-fold
higher than for LDL (21–23). The multivalent binding of apoE-
containing particles leading to the cross-linking of LDLrs may
explain the delayed perinuclear lysosomal targeting of
b-VLDL, VLDL, and (LPL-treated) VLDL as compared with
LDL after equally rapid endocytosis by macrophages (24–26),
human fibroblasts (27), and HepG2 cells (28), respectively.
Another difference between LDL and TG-rich lipoproteins may
be that their apolipoprotein components differ in their suscep-
tibility to intracellular degradation. Preliminary data on radio-
iodinated apoE emulsions and LDL suggest that, in contrast to
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the efficient degradation of apoB, the degradation of apoE may
be retarded, whereas fluorescently labeled lipids in TG-rich
particles and LDL followed a similar intracellular route toward
lysosomes (29, 30).
Besides its involvement in the cellular recognition and up-
take of TG-rich lipoprotein remnants and emulsions, apoE is
also hypothesized to play a role in the intracellular trafficking
of lipids (31–36). Initial data suggested that apoE affects the
transport and metabolism of free fatty acids and free choles-
terol released from the lysosomes (33). In addition, apoE ap-
peared to have a physiological role in the assembly and secre-
tion of VLDL (34–36). Although de novo synthesized apoE in
hepatocytes (37) may be used for VLDL assembly, lipoprotein-
derived apoE that is taken up by the cells may also serve this
purpose since apoE from radiolabeled VLDL remnants could be
recovered in hepatic Golgi fractions (exocytotic compartments)
after intravenous injection into mice (38).
The aim of the present study was to investigate whether
apoE that is internalized by hepatocytes can escape from lyso-
somal degradation and can be resecreted through retroendocy-
tosis. For this purpose, we utilized small apoE-containing TG-
rich emulsions that mimic the metabolic fate of TG-rich
lipoproteins in the blood (4, 39) and are exclusively taken up
via the LDLr in mice (18). The data show that apoE is indeed
relatively resistant to intracellular degradation as compared
with the cholesteryl oleate (CO) moiety of the emulsion both in
hepatoma cells in vitro (HepG2) and in hepatocytes in vivo
(C57Bl/6KH mice) and that apoE is resecreted at least in vitro.
Since these emulsions mimic TG-rich lipoproteins, we antici-
pate that apoE, which has been delivered to the hepatocyte as
a constituent of chylomicron remnants, can possibly be re-used
for intracellular lipid trafficking, such as the assembly and
secretion of VLDL, or may participate in lipoprotein remnant
internalization via the “secretion-recapture” pathway (40, 41).
MATERIALS AND METHODS
Animals—10–12-Week-old male C57Bl/6KH mice weighing 23–24 g
(from Broekman Instituut BV, Someren, The Netherlands) fed ad libi-
tum with regular chow were used for the in vivo experiments.
Chemicals—Recombinant human apoE (isoform E3) was a generous
gift from Dr. Tikva Vogel, Bio-Technology General Ltd., Rehovot, Israel,
and was supplied as a lyophilized powder containing 76% apoE, 11.7%
L-cysteine, and 12.0% NaHCO3 (42). ApoE was dissolved in phosphate-
buffered saline (PBS), pH 7.4 (2.0 mg/ml), and stored under argon at
280 °C. Bovine lactoferrin (bLf) was generously provided by Dr. Patrick
van Berkel, Pharming Technologies BV, Leiden, The Netherlands.
[1a,2a-3H]Cholesteryl oleate ([3H]CO) and 125I (carrier-free) in NaOH
were purchased from Amersham Pharmacia Biotech. Triolein (99%
pure) and egg yolk phosphatidylcholine (EYPC; 98%) were from Fluka,
Buchs, Switzerland. L-a-Lysophosphatidylcholine (99%), cholesterol
(.99%), bovine serum albumin (BSA, fraction V), ethyl mercurithiosa-
licylate, monensin, and heparinase I (EC 4.2.2.7) from Flavobacterium
heparinum were obtained from Sigma. Cholesteryl oleate (CO; 97%)
was from Janssen, Beersse, Belgium. Peroxidase type II (200 units/mg),
Precipath® L, and EDTA were from Roche Molecular Biochemicals.
HEPES was from Merck, and heparin (5000 units/ml) was from Leo
Pharmaceutical Products B.V., Weesp, The Netherlands. Multiwell cell
culture dishes were from Costar, Cambridge, MA. Dulbecco’s modified
Eagle’s medium (DMEM) and fetal calf serum (FCS) were obtained from
Flow Laboratories, Irvine, UK. All other chemicals were of analytical
grade.
Isolation of Lipoproteins—Human LDL (1.019 , d , 1.063 g/ml) and
HDL (1.063 , d , 1.21 g/ml) were isolated from the blood of healthy
volunteers by differential ultracentrifugation as described (43) and
dialyzed at 4 °C against PBS containing 1 mM EDTA, pH 7.4, with
repeated changes of buffer.
Protein Assay—Protein concentrations were determined according to
Lowry et al. (44) using BSA as a standard.
Radiolabeling of (Lipo)proteins—LDL was labeled with [3H]CO by
incubation with donor [3H]CO-containing liposomes, in the presence of
human lipoprotein-deficient serum. In short, liposomes were created by
sonication of 25 mg of EYPC and 200 mCi of [3H]CO using a Soniprep
150 (MSE Scientific Instruments, Crawley, UK) for 15 min at 18 mm
output, and concentrated by density gradient ultracentrifugation. Sub-
sequently, LDL was incubated with the liposomes (protein:liposomal
phospholipid 5 1:8, w/w) for 8 h at 37 °C under argon in the presence of
20 mM ethyl mercurithiosalicylate (45). LDL was purified by density
gradient ultracentrifugation and Superose 6® (Amersham Pharmacia
Biotech) gel filtration. The specific 3H activity was ;15 dpm/ng protein.
[3H]CO-labeled LDL, apoE, and bLf were radioiodinated at pH 10.0
with carrier-free 125I according to the ICl method (46). Free 125I was
removed by Sephadex G-50 medium gel filtration. More than 97, 98.5,
and 99.5% of the radiolabels in LDL, apoE, and bLf, respectively, were
10% trichloroacetic acid-precipitable. The specific 125I-activities of LDL,
apoE, and bLf were 114–301, 329–499, and 675 dpm/ng of protein,
respectively.
Preparation of (ApoE-Containing) Emulsions—Emulsions were prepared
according to the sonication and ultracentrifugation procedure of Redgrave
and Maranhao (47) from 100 mg of total lipid at a weight ratio triolein:
EYPC:lysophosphatidylcholine:CO:cholesterol of 70:22.7:2.3:3.0:2.0, using a
Soniprep 150 (MSE Scientific Instruments, UK) (4). For synthesis of radio-
labeled emulsions, 100–400 mCi of [3H]CO (67.3 mCi/mg) was added. An
emulsion fraction containing VLDL-sized particles was obtained by consec-
utive density gradient ultracentrifugation steps exactly as described (18).
The emulsions were homogeneous with respect to size (low polydispersity of
0.23–0.31) and the mean particle diameter was 44.3 6 2.6 nm (mean 6 S.D.;
n 5 6) as determined by photon correlation spectroscopy using a Malvern
4700 C system (Malvern Instruments, Malvern, UK) (18). The TG content of
the emulsion fractions was determined with the Roche Molecular Biochemi-
cals enzymatic kit for triacylglycerols. Association of apoE with the particles
occurred by incubation of emulsions with (125I-)apoE at TG:apoE 5 50:0.3
(low) and 50:3.0 (high) weight ratios for 30 min at 37 °C. Emulsion-bound
apoE was separated from free apoE using density gradient ultracentrifuga-
tion as described (39). The apoE contents of the reisolated emulsions were
4.6 6 1.1 mg/mg TG (50:0.3) and 34.2 6 2.6 mg/mg TG (50:3.0), which
corresponds to 4 6 1 and 27 6 2 molecules of apoE per particle. Emulsions
were stored at 4 °C under argon and used for characterization and metabolic
studies within 7 days following preparation.
Characterization of (Radiolabeled) ApoE—The (radiochemical) pu-
rity of apoE as well as the presence of disulfide-linked apoE ho-
modimers (48) were checked using 10% SDS-PAGE under non-reducing
conditions, using Kaleidoscope prestained molecular weight standards
as reference proteins. Resulting gels were stained for protein with
Coomassie Blue R-250 or assayed for 125I activity by exposure of dried
gels to Kodak X-Omat films. In addition, the homodimer content and
the aggregation state of (emulsion-bound) 125I-apoE was examined by
fast protein liquid chromatography (SMART system; Amersham Phar-
macia Biotech), using a Superdex® 200 column at a flow rate of 50
ml/min and with 50 mM NaPi, 0.15 M NaCl, pH 7.4, in the absence or
presence of 0.5% SDS as eluent.
Culture of HepG2 Cells—HepG2 cells were cultured at 37 °C in a
humidified 5% CO2, 95% air atmosphere in 25-cm
2 flasks containing
DMEM supplemented with 10% (v/v) heat-inactivated FCS, 20 mM
HEPES, 10 mM NaHCO3, 100 units/ml penicillin, and 100 mg/ml strep-
tomycin. At 6–7 days prior to each experiment, cells were seeded into
2-cm2 12-well dishes. At 24 h before the assays, cells were washed with
DMEM containing 1% BSA and were further incubated with DMEM
containing 10% (v/v) lipoprotein-deficient serum instead of FCS.
Cell Binding, Association, and Degradation Studies—Binding, asso-
ciation, and degradation studies were performed essentially as de-
scribed previously (28). For some experiments, cells were pretreated
with heparinase I for 2 h at 37 °C (14). Cells were washed three times
(DMEM 1 1% BSA) and were incubated at 4 or 37 °C with 0.5 ml of the
same medium with the indicated amounts of radiolabeled LDL or emul-
sions (3H or 125I), in the absence or presence of an excess of unlabeled
particles. After incubation, the cells were cooled to 0 °C, and the incu-
bation media were removed. The cells were washed three times with
PBS 1 0.1% BSA, once with PBS, and were dissolved in 1 ml of 0.2 M
NaOH. Aliquots of media and cell lysates were counted for 3H or 125I
radioactivity, and aliquots of the cell lysates were used for protein
determination. Degradation of 125I-protein in the medium was deter-
mined by separating 125I-protein from degradation products by 10%
trichloroacetic acid precipitation as described (19). To determine the
intracellular hydrolysis of [3H]CO into [3H]cholesterol, total lipid was
extracted according to Bligh and Dyer (50) and separated using thin
layer chromatography (heptane:diethyl ether:acetic acid 5 60:40:1, v/v).
CO (Rf 0.85) and cholesterol (Rf 0.23) were visualized with iodine vapor,
scraped off, and counted in 15 ml of Hionic Fluor (Packard Instrument
Co.). Using this method, 99.6% of the emulsion-associated 3H radioac-
tivity appeared as [3H]CO.
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Intracellular Processing and Retroendocytosis—Cells were preincu-
bated in the presence of 125I-apoE-containing emulsions (60 mg of TG/
ml) for 3 h at 18 °C, which does not impair binding and endocytosis, but
blocks the fusion of endosomes with lysosomes. As a result, cell-associ-
ated emulsions accumulate in the early endosomal compartment, with-
out being degraded (51, 52). Cells were washed with DMEM 1 1% BSA
to remove unbound ligand, and cell surface-bound apoE was released by
a subsequent wash with heparin (770 units/ml in DMEM 1 1% BSA)
(53, 54). Cells were washed once with PBS 1 0.1% BSA and further
incubated at 37 °C with 0.5 ml of DMEM 1 1% BSA in the absence or
presence of HDL (0.35 mg of protein/ml) or apoE-deficient emulsion
(0.50 mg of TG/ml). After incubation, the media and cells were treated
as described above. In addition, 500-ml aliquots of media, combined
from triplicate samples, were subjected to density gradient ultracen-
trifugation at 40,000 rpm for 18 h at 4 °C as described (43). Tubes were
fractionated (24 3 0.5 ml) from top to bottom using a Multiprobe 104DT
Robotic System from Packard Instrument Co., and fractions were
counted for 125I activity. Subsequently, 400-ml fraction aliquots were
subjected to 10% trichloroacetic acid precipitation to separate 125I and
125I-tyrosine from intact 125I-apoE. To identify the radioactivity within
the emulsion and HDL-containing fractions as intact apoE or degrada-
tion products, the fractions were desalted by dialysis against 100-fold
diluted PBS, freeze-dried, and subjected to 4–20% gradient SDS-PAGE
under non-reducing conditions. The radioactivity on the gel was visu-
alized by imaging using a Packard Instant Imager (Hewlett-Packard
Co., Palo Alto, CA).
Liver Uptake and Serum Decay of Emulsions in Mice—Mice were
anesthetized by subcutaneous injection of a mixture of ketamine (120
mg/kg body weight), Thalamonal (0.03 mg/kg fentanyl and 1.7 mg/kg
droperidol), and Hypnorm (1.2 mg/kg fluanisone and 0.04 mg/kg fent-
anyl citrate), and the abdomens were opened. [3H]CO or 125I-apoE-
labeled apoE-containing emulsions (reisolated after incubation at a
ratio TG:apoE 5 50:3.0, w/w) were injected (150 mg of TG, correspond-
ing with 5 mg of apoE) via the inferior vena cava. At the indicated times,
blood samples (,50 ml) and liver lobules were taken and processed as
described in detail (18). Radioactivity in duplicate serum samples of 10
ml was counted either directly (125I) or in 2.5 ml of Emulsifier Safe
(Packard Instrument Co.) (3H). The total serum volumes of C57Bl/6KH
mice were 1.068 6 0.066 ml, as previously determined (18). Radioac-
tivity in liver samples was also counted directly (125I) or in 15 ml of
Hionic Fluor (Packard Instrument Co.) after solubilization in 0.5 ml of
Soluene®-350 (Packard) for 5 h at 65 °C (3H). Radioactivity values are
corrected for the serum radioactivity (84.7 ml/g wet weight) present at
the time of sampling (18). Since liver lobules were partly used for
determination of particle degradation, total liver weights were esti-
mated from the following equation: liver mass (g) 5 20.204 1 (0.0560 3
body mass (g)).
Intrahepatic Processing of Emulsions in Mice—To determine the
intrahepatic degradation of 125I-apoE, aliquots of liver lobules were
immediately frozen in liquid N2, homogenized in ice-cold PBS, pH 7.4,
and subjected to 10% trichloroacetic acid precipitation. The intrahe-
patic conversion of [3H]CO into [3H]cholesterol was assayed after sim-
ilar freezing and homogenization of liver aliquots. Lipids were extracted
and separated as described above.
RESULTS
Purity of Lipid-free and Emulsion-associated ApoE—The (ra-
diochemical) purity of apoE was assessed by 10% SDS-PAGE
under non-reducing conditions (Fig. 1A). As expected, apoE
appeared to be present mainly as a 34-kDa protein as deter-
mined by staining with Coomassie Blue R-250. In addition, a
minor protein band with an apparent mass of ;100 kDa was
observed, which has previously been shown to represent the
disulfide-linked dimer of apoE (48). Accordingly, this band was
not detected after reduction with b-mercaptoethanol (not
shown). After radiolabeling of apoE, 96% of the 125I-activity
could be recovered at the position of monomeric apoE (34 kDa).
Elution of radiolabeled apoE on a Superdex® 200 column
showed mainly radioiodinated tetramers (eluting in between
mouse IgG and BSA) in addition to monomers (eluting simi-
larly as ovalbumin) and a small amount of higher aggregates
(eluting before IgG) (Fig. 1B). Gel filtration of 125I-apoE using
SDS-containing eluent confirmed the presence of a small por-
tion of 125I-labeled homodimers (eluting at a position close to
that of BSA) (Fig. 1C) that disappeared upon reduction with
b-mercaptoethanol (not shown). In contrast, emulsion-bound
125I-apoE was only monomeric, which confirms earlier obser-
vations that the interaction of apoE homodimers with lipidic
particles does not withstand ultracentrifugation conditions
(48).
Binding of ApoE-containing Emulsions to HepG2 Cells—To
establish the contribution of HSPG and the LDLr to the recog-
nition of apoE emulsions by HepG2 cells, binding experiments
were conducted at 4 °C (Fig. 2). Removal of HSPG from the cell
surface by treatment with heparinase (2.5 units/ml) resulted in
FIG. 1. Electrophoresis and chromatography of (radiolabeled)
apoE. A, unlabeled (lane 1) and 125I-labeled (lanes 2 and 3) apoE (4 mg)
were added to SDS incubation buffer without b-mercaptoethanol (non-
reducing conditions) and subjected to 10% SDS-PAGE. After electro-
phoresis, proteins were stained with Coomassie Blue R-250 (lanes 1 and
2), and 125I activity was detected by autoradiography (3). B and C,
lipid-free (E) and emulsion-bound (l ) 125I-apoE (1.6 mg) were eluted on
a Superdex® 200 column using 50 mM NaPi, 0.15 M NaCl, pH 7.4, in the
absence (B) or presence (C) of 0.5% SDS, and fractions were analyzed
for radioactivity. Arrows indicate the void volume (V0) and the elution
positions of mouse IgG (Mr 155,000), BSA (Mr 66,000), and ovalbumin
(Mr 45,000).
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a 45% reduction of the binding of bLf. In contrast, only a minor
effect of heparinase treatment (12–17% reduction) was ob-
served on the binding of both the [3H]CO-labeled and 125I-
labeled apoE-enriched emulsions (incubated at a TG:apoE 5
50:3 weight ratio). It is thus evident that HSPG play only a
minor role in the binding of the apoE-enriched emulsion (Fig.
2A). The binding of both the [3H]CO-labeled and 125I-labeled
apoE-enriched emulsions was dose-dependently inhibited by
an excess of unlabeled particles (Fig. 2, B and C). LDL also
efficiently inhibited the binding of the radiolabeled apoE emul-
sions for at least 93–94% (Fig. 2, B and C). Taking these data
together, it is evident that the applied apoE-emulsion particles
are also almost exclusively recognized by the LDLr on HepG2
cells in vitro, whereas HSPG play only a minor role in particle
recognition.
Association and Degradation of ApoE-containing Emulsions
by HepG2 Cells—To evaluate whether apoE is relatively resist-
ant to intracellular degradation, the metabolic fate of the
[3H]CO and 125I-apoE moiety of apoE emulsions (incubated at
a TG:apoE 5 50:3 weight ratio) in HepG2 cells during incuba-
tion at 37 °C was determined (Fig. 3). The CO and apoE com-
ponents showed a similar time-dependent cellular uptake.
However, whereas the hydrolysis of CO started within 30 min
after incubation and was very effective (47% of the total uptake
at 4 h), the degradation of the apoE moiety started slowly
($120 min) and was to a much lower extent (19% at 4 h). The
emulsion particles were taken up as unity since the total up-
take of both the CO and apoE moieties (11.6 nmol of CO and 5.3
mg of apoE per mg of cell protein at 4 h) is proportional to the
ratio of these components in the emulsion (1.9 nmol of CO per
mg of apoE). The involvement of apoE in the cellular uptake of
the emulsion was confirmed by a 5-fold increase in the total CO
uptake as compared with the apoE-free emulsion (not shown).
Previous studies have shown that internalization of LDL by
the LDLr results in complete lysosomal degradation of both its
lipid and protein components (19, 20). Incubation of HepG2
cells with [3H]CO or 125I-apoB-labeled LDL (20 mg of protein/
ml), which resulted in a similar rate of particle uptake as
compared with apoE emulsions (;1012 particles per mg of cell
protein at 4 h), led to the rapid onset of both [3H]CO hydrolysis
and 125I-apoB degradation (both within 30 min) (not shown). In
Fig. 4 the relative apolipoprotein degradation rates, as calcu-
lated from the fraction of degraded apolipoprotein (degraded/
total uptake 125I-protein) divided by the fraction of hydrolyzed
CO (hydrolyzed/total uptake [3H]CO), are shown for emulsion-
associated apoE and LDL-associated apoB. It appears that
apoE is far more resistant to intracellular degradation as com-
pared with apoB. These data thus indicate that apoE emul-
sions, after LDLr-mediated uptake, may have a different intra-
cellular fate as compared with LDL, as a result of which apoE
may (partially) escape from lysosomal degradation.
Intracellular Processing and Retroendocytosis of ApoE by
HepG2 Cells—Since internalized apoE was shown to be resist-
ant to intracellular degradation, it was reasoned that intact
apoE may be recovered in the medium after cellular uptake
through retroendocytosis. To evaluate this hypothesis, apoE
emulsions were incubated with cells for 3 h at 18 °C (51, 52).
Unbound particles were removed by extensive washing with
DMEM/BSA. Residual cell surface-associated 125I-activity was
released by 770 units/ml heparin (53, 54), which led to a reduc-
tion in total cell association of ;30%. The cells were further
incubated at 37 °C in the absence or presence of protein-free
FIG. 2. Binding of apoE emulsions
to HepG2 cells. A, cells were treated (2 h
at 37 °C) with heparinase (0–5 units/ml),
washed, and incubated (3 h at 4 °C) with
[3H]CO-labeled or 125I-labeled apoE-en-
riched emulsions (previously incubated at
TG:apoE 5 50:3.0; 60 mg of TG/ml) or
125I-bLf (2 mg/ml). B and C, alternatively,
non-pretreated cells were incubated (3 h
at 4 °C) with [3H]CO-labeled or 125I-la-
beled apoE-enriched emulsions (60 mg of
TG/ml) in the presence of increasing con-
centrations of unlabeled apoE-enriched
emulsions or LDL. A–C, after incubation,
cells were washed, lysed, and cell protein
and cell-associated radioactivities were
determined. Data are expressed as per-
centage of binding in the absence of treat-
ment or competitor (55.3 6 3.4 and 51.5 6
3.6 ng of protein per mg of cell protein for
[3H]CO-labeled and 125I-labeled emul-
sions, respectively). Values are means 6
S.D. of triplicate incubations.
FIG. 3. Intracellular processing and apoE emulsions in HepG2
cells. Cells were incubated at 37 °C with [3H]CO-labeled (A) or 125I-
labeled (B) apoE-enriched emulsions (previously incubated at TG:
apoE 5 50:3.0; 60 mg of TG/ml). At the indicated times, the cells were
washed and lysed, and cell protein was determined. Subsequently, total
lipids were extracted, and non-hydrolyzed (E) and hydrolyzed (l )
[3H]CO were separated by thin layer chromatography. Alternatively,
cellular associated 125I-activity was measured (E), and 125I-degradation
products in the medium ( l ) were determined by 10% trichloroacetic
acid precipitation. Values are means 6 S.D. of triplicate incubations.
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emulsion or HDL in the medium as potential acceptors of
secreted apoE (55–57) (Fig. 5). A time-dependent decrease in
the cellular association of apoE was observed in the absence of
acceptor, with 52 6 4% of the radioactivity still associated with
the cells after 60 min of incubation. At this time point, the cell
association was reduced to 45 6 1% (Student’s t test; p , 0.05)
and 38 6 3% (p , 0.01) in the presence of the protein-free
emulsion or HDL, respectively. The presence of these acceptors
had no effect on the degradation rate of 125I-apoE but did result
in a significantly increased secretion rate of trichloroacetic
acid-precipitable radioactivity (representing intact protein) as
compared with the absence of acceptor (repeated measures
analysis of variance, p , 0.01 and p , 0.001, respectively).
More specifically, whereas 18.6 6 0.8% of the radioactivity
secreted into the medium was recovered as precipitable protein
after 4 h of incubation in the absence of acceptor, 23.0 6 0.7
(Student’s t test; p , 0.01) and 29.8 6 1.9% (p , 0.001) of the
radioactivity could be precipitated from the medium in the
presence of emulsion and HDL, respectively (Fig. 5).
Loading the cells with [3H]CO-labeled apoE emulsions at
18 °C led to the hydrolysis of the vast majority of radiolabel into
[3H]cholesterol (.90%) after 4 h of incubation at 37 °C,
whereas hardly any intact [3H]CO could be detected in the
medium (,3% of the initially cell-associated radiolabel) (not
shown). In the same experimental set up, loading of HepG2
cells with 125I-LDL (10 mg/ml) resulted in a decrease of cellular
125I-apoB radioactivity with a half-life of ;2 h. In contrast to
apoE, virtually all radioactivity released into the medium was
trichloroacetic acid-soluble (.95%) (data not shown), which is
in full accordance with our previous observations (28).
To evaluate whether the secreted apoE is still functional in
that it recombines with lipids, aliquots of the media were
harvested after 3 h of incubation and subjected to density
gradient ultracentrifugation (Fig. 6). Whereas both intact and
degraded apoE were detected in the bottom fractions of the
tubes from media without acceptor (Fig. 6A), 45 and 50–60% of
the trichloroacetic acid-precipitable radioactivity were recov-
ered in the emulsion and HDL fractions when the respective
acceptors were present in the media (Fig. 6, B and C). The
integrity of apoE on these particles was confirmed by the de-
tection of a radiolabeled 34-kDa protein in these fractions after
protein separation by non-reducing 4–20% gradient SDS-
PAGE, followed by imaging (insets in Fig. 6, B and C). Appar-
ently, both emulsion particles and HDL can function as accep-
tors of secreted apoE, albeit that HDL is more effective than
emulsion particles in stimulation of the total release of apoE
under the given conditions (Fig. 5).
Intrahepatic Processing of ApoE Emulsions in Mice—Subse-
quently, we investigated whether the finding that apoE can
escape intracellular degradation upon entry of the lysosomal
route is relevant for the intrahepatic metabolism of apoE emul-
sions in the intact animal. We have previously shown that
intravenous injection of the protein-free [3H]CO-labeled emul-
sion (150 mg of TG) into C57Bl/6KH mice results in the
monophasic elimination of radiolabel from the serum with a
half-life of ;45 min. Concomitantly, a progressively increasing
LDLr-dependent liver uptake reaching ;45% of the injected
dose at 45 min after injection was observed (18). As shown in
Fig. 7, preassociation of apoE with the [3H]CO-labeled emul-
sion accelerated the serum clearance (t1⁄2 , 10 min) and liver
uptake (;50% at 20 min) of the emulsion. The initial rate of
serum clearance and liver uptake of the protein and lipid com-
ponents of the emulsion were essentially similar (Fig. 7). In
contrast, injection of an equal dose of 125I-apoE in a lipid-free
state led to the rapid elimination of 80% of the injected dose
from the serum within 2 min, with a high uptake by the liver
(70% at 5 min after injection).
In general, the intrahepatic degradation of endocytosed apo-
lipoproteins leads to rapid elimination of radiolabel from the
liver and nonspecific distribution over the body (58), which also
appears to occur with lipid-free apoE (Fig. 7). The hepatic
uptake of lipid-associated apoE (43.7 6 2.3% of the dose at 20
min after injection) was not coupled to rapid degradation, as
36.3 6 2.1% was still present within the liver at 60 min after
injection. The stability of lipid-associated apoE was also con-
firmed by a low level of degradation products in the liver,
reaching only 8.8 6 0.2% of the recovered radioactivity at 60
min after injection (Fig. 8). In contrast, the intrahepatic hy-
drolysis of [3H]CO was rapid and efficient, with 50% hydrolysis
achieved at 45 min after injection.
DISCUSSION
Radioiodination of TG-rich lipoproteins results in the label-
ing of various apolipoproteins (especially apoCs) that may all
have a different susceptibility to proteolysis, which hampers
the interpretation of the metabolic fate of apoE. In order to
chase the intracellular fate of apoE only, we thus decided to
utilize VLDL-sized TG-rich emulsions (44 6 3 nm) that can be
enriched with radiolabeled apoE (4, 18). The metabolic behav-
ior of these particles in vivo is completely dependent on the
presence of the LDLr, as determined by kinetic studies on
[3H]CO-labeled emulsions in wild-type versus LDLr-deficient
mice (18). As a reference for LDLr-mediated processing of sub-
strates, we used LDL, which only contains a single copy of apoB
that is labeled upon radioiodination. Whereas radioiodinated
apoE did contain some disulfide-linked apoE homodimers,
analysis of emulsion-bound 125I-apoE confirmed that the radio-
activity was associated with 34-kDa apoE only. It can thus be
excluded that the results are confounded by the presence of
apoE homodimers (48).
The total binding values of the emulsions, calculated from
the specific radioactivities of either the [3H]CO-labeled and
125I-labeled emulsions, were similar (55.3 6 3.4 and 51.5 6 3.6
ng of protein/mg of cell protein, respectively), which indicates
that the apoE-emulsion particle binds to the cell as a unity,
without preferential binding of either the lipid or protein moi-
ety (Fig. 2). The binding of the emulsion to HepG2 cells ap-
peared to be largely mediated by the LDLr (;90% of the total
FIG. 4. Degradation rates of apoE versus apoB in HepG2 cells.
Cells were incubated at 37 °C with [3H]CO- or 125I-labeled apoE-en-
riched emulsions (60 mg of TG/ml) or LDL (20 mg of protein/ml). At the
indicated times, non-hydrolyzed and hydrolyzed [3H]CO as well as
cell-associated and degraded 125I-apolipoprotein were determined as
described in the legend to Fig. 1. The apolipoprotein degradation rates
(fraction-degraded 125I-apolipoprotein/fraction-hydrolyzed [3H]CO)
were calculated. Values are means 6 S.D. of triplicate incubations.
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binding), whereas HSPG contributed for only a low extent
(;10%) as determined after treatment of the cells with hepa-
rinase. In accordance with previous observations by Ji and
Mahley (59), heparinase treatment inhibited the binding of bLf
to HepG2 cells by 45%, which demonstrates that HSPG had
been effectively removed. The finding that HSPG are hardly
involved in the binding of apoE emulsion particles is in agree-
ment with our previous observations that, as opposed to LPL,
apoE is not essential for the binding of b-VLDL to HSPG (60).
The association and degradation of the emulsion by HepG2
cells appeared to be dependent on the presence of apoE. The
apoE-deficient emulsion showed a low cellular association and
degradation, which was not substantially increased by the ad-
dition of 4 6 1 molecules of apoE per emulsion particle, ob-
tained at a TG:apoE 5 50:0.3 weight ratio (not shown). In
contrast, the addition of a physiologically relevant number of
apoE molecules per particle (27 6 2 at a 50:3 weight ratio),
which is similar to the apoE content of rat VLDL (29 mg/mg of
TG, corresponding to 26 molecules per particle) (61), resulted in
a 5-fold increased cellular association of the emulsion CO core.
These findings correspond well with the previously reported
stimulatory effect of apoE on LDLr-mediated uptake of TG-rich
emulsions by J774 macrophages (33).
After cellular uptake of LDL, both its protein and lipid con-
stituents follow the same lysosomal pathway (19, 20), although
the initial rate of CO hydrolysis appears to be faster than apoB
degradation (Fig. 4). This may be explained by the fact that full
protein degradation (leading to release of 125I-Tyr) requires
multiple enzymatic steps, whereas CO hydrolysis is achieved
by a single enzymatic cut. In addition, the optimal conditions
for efficient hydrolysis by cholesteryl esterases may be reached
at an earlier stage in the endosomal pathway than for pro-
teases. Emulsion-derived apoE is much more resistant to in-
tracellular degradation as compared with LDL-derived apoB,
as evident from a later onset of protein degradation (120 versus
30 min) and a much lower degradation rate (Fig. 4). These data
are in full agreement with the observed relative intracellular
stability of apoE as compared with apoB after uptake by hu-
man fibroblasts and mouse J774 macrophages (30).
After pulse labeling of HepG2 cells with apoE emulsions at
18 °C, and subsequent incubation at 37 °C, a time-dependent
release of intact apoE into the medium (14% of the initially
endocytosed apoE) could be detected. The release of apoE was
increased to up to 20 and 26% in the presence of the protein-
free emulsion or HDL in the medium, respectively. The gradual
reappearance of intact 125I-apoE in the medium cannot be
FIG. 5. Intracellular processing of
endocytosed apoE in HepG2 cells.
Cells were incubated for 3 h at 18 °C with
125I-apoE emulsions (previously incu-
bated at TG:apoE 5 50:3.0; 60 mg of TG/
ml), extensively washed in the presence of
770 units/ml heparin, and further incu-
bated in the absence (A) and presence of
emulsion (0.50 mg of TG/ml) (B) or HDL
(0.35 mg of protein/ml) (C) starting at t 5
0. At the indicated times, the amount of
cell-associated 125I radioactivity ( l ), 125I-
degradation products in the medium (E),
and trichloroacetic acid-precipitable 125I-
protein () in the medium were deter-
mined. Data are expressed as percentage
of initially cell-associated 125I activity
(41.2 6 4.4 ng of apoE per mg of cell
protein). Values are means 6 S.D. of trip-
licate incubations.
FIG. 6. Density gradient ultracen-
trifugation profiles of intact and de-
graded 125I-apoE in media of HepG2
cells. Cells were incubated with 125I-
apoE emulsions in the absence (A) or
presence of emulsion (B) or HDL (C) as
described in the legend to Fig. 5. At 180
min, media were collected and subjected
to density gradient ultracentrifugation.
The gradients were subdivided from top
(fraction 1) to bottom (fraction 24), and
10% trichloroacetic acid precipitation on
400-ml aliquots was performed to discrim-
inate between degraded (E) and intact ( l )
protein. Insets, emulsion-containing frac-
tions (B, fractions 1 and 2) and HDL-con-
taining fractions (C, fractions 13–17) were
dialyzed and subjected to non-reducing
4–20% SDS-PAGE, and radioactivity was
visualized by imaging.
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explained by a slow release of apoE that was incompletely
washed from the cell surface after incubation at 18 °C, since
lipid-free 125I-apoE that was bound to the cell surface after
incubation for 3 h at 4 °C was effectively removed by heparin
(770 units/ml).
Previous pulse-chase experiments with radioiodinated VLDL
also resulted in the appearance of intact protein in the medium
(28). Our present data rule out that secretion of intact particles
occurs upon endocytosis but rather show that apoE can selec-
tively undergo retroendocytosis. By contrast, most LDL-de-
rived apoB was recovered in the medium in a degraded state
(.95%), which confirms previous observations (28, 62). It is
thus clear that retroendocytosis is a unique feature of apoE as
compared with apoB. In this study, we have not examined the
intracellular fate of the other apolipoprotein constituents of
TG-rich lipoproteins. A recent paper suggests that apoCs may
also be released from cells upon internalization (54).
We observed that apoE, which is released from cells by
retroendocytosis, can recombine with both the protein-deficient
emulsion and HDL. Both the presence of the emulsion and
HDL in the medium stimulated retroendocytosis of apoE, with-
out an effect on apoE degradation. In all cases, the rate of apoE
retroendocytosis may even be underestimated, since it is
known that a considerable amount of newly synthesized apoE
remains associated with cells instead of being secreted into the
medium (56, 63). In addition, newly synthesized apoE that
binds to the cell surface may partially be proteolytically de-
graded upon re-entry into the cell (57). It has been shown
before that the presence of serum or isolated lipoproteins may
prevent the degradation of re-endocytosed apoE by triggering
the release of apoE from HepG2 cells (57) and macrophages
(55), but it is not clear from these studies and our observations
whether the applied concentration of HDL in the medium can
extract all of the secreted apoE from the cell surface, especially
since radiolabeled apoE must compete with HepG2-derived
apoE for the binding to HDL.
In an attempt to examine the physiological relevance of our
in vitro findings for the situation in vivo, we also determined
the intrahepatic handling of the apoE-enriched emulsion after
intravenous injection into mice. Indeed, it appeared that after
simultaneous hepatic uptake of both the particle core (reflected
by the CO moiety) and the preassociated apoE (45–50% of the
injected dose at 20 min after injection), only 10–20% of the
apoE is degraded in contrast to as much as 75% of the CO
moiety at 1 h after injection (Figs. 7 and 8). It is tempting to
assume that in vivo, intrahepatic apoE may also undergo ret-
roendocytosis, resulting in the release of apoE from hepato-
cytes with subsequent attachment to HSPG in the space of
FIG. 7. Liver uptake and serum decay
of apoE emulsions in mice. [3H]CO-la-
beled (E) or 125I-apoE-labeled (l ) apoE
emulsions (150 mg of TG, corresponding to 5
mg of apoE) or lipid-free 125I-apoE (5 mg) (),
were injected into anesthetized mice. At the
indicated times, the liver uptake (left) and
serum decay (right) were determined. Liver
values are corrected for serum radioactivity.
Values are means 6 variation of two
experiments.
FIG. 8. Intrahepatic degradation of
apoE emulsions in mice. [3H]CO-la-
beled (left) or 125I-apoE-labeled (right)
apoE emulsions (150 mg of TG) were in-
jected into anesthetized mice. At the indi-
cated times, liver lobules were taken, im-
mediately frozen in liquid N2, and
homogenized in ice-cold PBS. After total
lipid extraction, intact ( l ) and hydrolyzed
(E) [3H]CO were separated by thin layer
chromatography. Alternatively, intact
125I-apoE (l ) was separated from degra-
dation products (E) by 10% trichloroacetic
acid precipitation. Values are means 6
variation of two experiments.
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Disse or circulating lipoproteins such as HDL. However, this
hypothesis is hard to establish conclusively under the present
experimental conditions.
The mechanism of apoE retroendocytosis remains an intrigu-
ing issue. In theory, apoE may be shuttled through CURL as is
the case for transferrin, which returns to the cell membrane
after having delivered its iron load (64, 65). The fact that the
recycling of transferrin in HepG2 cells occurs with a half-time
of less than 10 min (64), whereas apoE is slowly and gradually
released from these cells after pulse labeling, suggests that
other mechanisms should account for escaping degradation. A
recent paper (54) indeed showed by microscopic analysis that
incubation of fibroblasts with TG-rich lipoproteins and trans-
ferrin results in the appearance of apoE and transferrin in
distinct endosomal vesicles. Alternatively, apoE may escape
degradation via reversible aggregation into multimeric com-
plexes at low pH, as suggested by Chen et al. (66), but this
hypothesis evidently requires further investigation.
In conclusion, we have shown that apoE is relatively resist-
ant to degradation after cellular uptake by hepatoma cells in
vitro and hepatocytes in vivo and that retroendocytosis of apoE
occurs at least in vitro. It is already known that newly synthe-
sized apoE that is secreted and bound to cell surface HSPG can
be re-endocytosed upon the binding of lipoproteins (so called
secretion-recapture pathway) (40, 41, 57). Taking these data
together, it can be envisioned that apoE, after synthesis and
secretion by the hepatocyte, can be recycled by the cell several
times until final degradation occurs. It may also be possible
that endocytosed apoE is involved in the assembly and secre-
tion of VLDL by hepatocytes (34, 35). Provided that the stabil-
ity of endocytosed apoE can also be demonstrated in extrahe-
patic cells such as macrophages, our data may also implicate a
role of retroendocytosed apoE in reverse cholesterol transport
and regression of atherosclerosis.
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